One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Updates on lymphogranuloma venereum
G. Ciccarese,F. Drago,A. Rebora,A. Parodi
doi : 10.1111/jdv.17468
Volume 35, Issue 8 p. 1606-1607
Lymphogranuloma venereum (LV) is a sexually transmitted infection (STI) caused by Chlamydia trachomatis (CT) genovars L1, L2, L3. Infection by these CT genotypes may result in more invasive disease compared to other genotypes (A–K), since L1–L3 strains have tropism not only for the epithelial surfaces but also for the lymphatic tissues. After an incubation period of 1–2 weeks, the infection manifests with painful small erosions or ulcers in the site of the sexual contact (genitals, anus, rectum, oropharynx) lasting for 2–3 days and followed by painful, often unilateral, regional lymphadenopathy. The inguinal/femoral lymph nodes may become tender and fluctuant (buboes) and may undergo necrosis. Their rupture occurs in 30% of cases. During this stage, systemic symptoms such as fever, headache, nausea, anorexia and myalgia may occur.
Aquagenic wrinkling of the palms and cystic fibrosis diagnosis
G. Grimalt,M. Carbonell,R. Grimalt
doi : 10.1111/jdv.17445
Volume 35, Issue 8 p. 1608-1608
Aquagenic wrinkling of the palms (AWP) is an exaggerated and early wrinkling occurring after brief immersion to water,1, 2 AWP is also called aquagenic palmoplantar keratoderma, transient reactive papulo translucent acrokeratoderma, aquagenic syringeal keratoderma or transient aquagenic hyperwrinkling.3, 4 It is a transitory condition which occurs 2–3 min after exposure to water and patients in addition to hyper wrinkling might also show white papules, oedema, and feel a tingling sensation and even pain as the water exposure time increases.
Pioneers in Dermatology and Venereology: an interview with Professor Ricardo Luis Galimberti
R.L. Galimberti
doi : 10.1111/jdv.17446
Volume 35, Issue 8 p. 1609-1611
Smallpox in art: considerations on some of its medical and social aspects
F.M. Galassi,E. Varotto
doi : 10.1111/jdv.17266
Volume 35, Issue 8 p. 1612-1613
Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes
P.V. Chernyshov,L. Tomas-Aragones,A.Y. Finlay,L. Manolache,S.E. Marron,F. Sampogna,S. Spillekom-van Koulil,N. Pustisek,A. Suru,A.W.M. Evers,C. Salavastru,A. Svensson,D. Abeni,C. Blome,F. Poot,G.B.E. Jemec,D. Linder,M. Augustin,A. Bewley,S.S. Salek,J.C. Szepietowski
doi : 10.1111/jdv.17370
Volume 35, Issue 8 p. 1614-1621
New treatment options may lead to an increased interest in using reliable and sensitive instruments to assess health-related quality of life in people with alopecia areata (AA). The purpose of this paper is to present current knowledge about quality of life assessment in AA. The dermatology-specific Dermatology Life Quality Index (DLQI) was the most widely reported health-related quality of life instrument used in AA. Three AA-specific (Alopecia Areata Symptom Impact Scale, Alopecia Areata Quality of Life Index and Alopecia Areata Patients' Quality of Life) and three hair disease-specific instruments (Hairdex, Scalpdex and ‘hair-specific Skindex-29’) were identified with a range of content and validation characteristics: there is little evidence yet of the actual use of these measures in AA. Scalpdex is the best-validated hair disease-specific instrument. Further extensive validation is needed for all of the AA-specific instruments. The European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes recommends the use of the dermatology-specific DLQI questionnaire, hair disease-specific Scalpdex and the alopecia areata-specific instruments the Alopecia Areata Symptom Impact Scale or Alopecia Areata Quality of Life Index, despite the limited experience of their use. We hope that new treatment methods will be able to improve both clinical signs and health-related quality of life in patients with AA. In order to assess the outcomes of trials on these new treatment methods, it would be helpful when further development and validation of AA-specific instruments is being encouraged and also conducted.
Anal cancer screening and prevention: a review for dermatologists
J. McGovern,C. Fuller,K. Burris
doi : 10.1111/jdv.17263
Volume 35, Issue 8 p. 1622-1627
The incidence of and mortality from anal cancer, predominantly squamous cell carcinoma (SCC), have been increasing since the 1980s, during an era when many common malignancies have seen decreases in mortality. Dermatologists may be more likely to see patients at an increased risk for anal SCC, such as those living with HIV, MSM and those presenting for management of anogenital warts, yet there is little guidance in the field on how to manage these patients. We underwent a project to review the evidence surrounding screening and prevention of anal SCC. HPV vaccination, the main preventative measure for anal SCC, is often underutilized and may not be effective for those most at risk. Screening methods currently include high-risk HPV and anal cytology testing, with high-resolution anoscopy (HRA) reserved for biopsy and confirmatory testing. High-risk HPV testing has been associated with high sensitivity for intraepithelial neoplasia, but low specificity in high-risk groups. Recent meta-analyses examining AIN detection using anal cytology estimate a similarly high sensitivity of 74–87%, with a relatively higher specificity (44–66%) for identifying high-grade AIN. HRA is the gold standard for diagnosis, but its accessibility and cost are deterrents from its use as a screening tool. Cervical cancer screening, initially adopted without significant evidence of its impact, has significantly decreased cervical cancer rates. The argument can be made that rates of anal SCC may also benefit from appropriate screening methods, particularly anal cytology. It is prudent for dermatologists to be aware of the methods available to them in the management of at-risk patients, the data supporting them, and the potential benefits of screening in order to counsel patients appropriately and address the increasing burden of disease.
Nondermatophyte mould onychomycosis
A.K. Gupta,R.C. Summerbell,M. Venkataraman,E.M. Quinlan
doi : 10.1111/jdv.17240
Volume 35, Issue 8 p. 1628-1641
Nondermatophyte moulds (NDMs) onychomycosis is often difficult to diagnose as NDMs have been considered contaminants of nails. There are several diagnostic methods used to identify NDMs, however, repeated laboratory isolation is recommended to validate pathogenicity. With NDM and mixed infection (dermatophytes plus NDM) onychomycosis on the rise, accurate clinical diagnosis along with mycological tests is recommended. Systemic antifungal agents such as itraconazole and terbinafine (e.g. pulse regimen: 1 pulse = every day for one week, followed by no treatment for three weeks) have shown efficacy in treating onychomycosis caused by various NDMs such as Aspergillus spp., Fusarium spp., Scopulariopsis brevicaulis, and Onychocola canadensis. Studies investigating topical therapy and devices for NDM onychomycosis are limited. The emergence of antifungal resistance necessitates the incorporation of antifungal susceptibility testing into diagnosis when possible, for the management of recalcitrant infections. Case studies documented in the literature show newer azoles such as posaconazole and voriconazole as sometimes effective in treating resistant NDM onychomycosis. Treatment with broad-spectrum antifungal agents (e.g. itraconazole and efinaconazole) and other combination therapy (oral + oral and/or oral + topical) may be considerations in the management of NDM onychomycosis.
Atopic dermatitis among children and adolescents in the Arctic region – a systematic review and meta-analysis
A.M. Andersson,A.S. Halling,N. Loft,L. Skov,A. Koch,E. Guttman-Yassky,J.P. Thyssen
doi : 10.1111/jdv.17276
Volume 35, Issue 8 p. 1642-1654
The prevalence of atopic dermatitis (AD) varies across the globe, and the clinical phenotype with racial background and ethnicity. AD in the Arctic region has only been scarcely studied. We performed a systematic review and meta-analysis to examine the prevalence, clinical manifestations and risk factors for AD among children and adolescents in the Arctic. Three medical databases PubMed, Embase and Web of Science were screened. All studies published between 1990 to 2020 with epidemiologic data on AD in children and adolescents in the Arctic region, were included. Data were extracted and a meta-analysis was performed to obtain pooled proportions and incidences with 95% confidence intervals (CI). We identified 21 studies from 8 different Arctic regions with 31 403 participants. The cumulative incidence of AD was 23% (95% CI 20–26) and 1-year prevalence was 19% (95% CI 15–25). The incidence of AD was higher in the Arctic parts of Scandinavia and lower in Greenland and Russia. Children of indigenous descent had a slightly lower incidence of AD (19%, 95% CI 13–26) compared to the overall population. The dominant phenotype of AD was mild to moderate flexural dermatitis with facial involvement. Asthma and allergic rhinitis were common and observed in 20–30% of children with AD. In conclusion, AD is highly prevalent in the Arctic, but varies between regions and races. Indigenous children living in less urbanized countries appear to have a slightly lower risk of AD. Future studies should confirm this and examine whether this correlation relates to behavioural differences or genetic signature.
Clinical manifestations and treatment outcomes in degos disease: a systematic review
P.J. Kim,Y. Lytvyn,N. Kashetsky,A. Bagit,A. Mufti,J. Yeung
doi : 10.1111/jdv.17311
Volume 35, Issue 8 p. 1655-1669
Degos disease (atrophic papulosis) is a rare vasculopathy with cutaneous and systemic manifestations. Although potentially fatal, the characteristics of and treatments for Degos disease variants are not adequately described. We conducted a systematic review to summarize cutaneous and systemic presentations, treatments and outcomes of malignant (MAP) and benign (BAP) variants of Degos disease. A comprehensive search was conducted on Embase, MEDLINE, CINAHL and CENTRAL on 27 October 2020, which yielded 254 original studies reporting cases of Degos disease. A total of 357 patients were included in the analysis. Mean age of onset was 33.9 years. MAP was most commonly reported (63.8%, n = 228/357), with 56.6% (n = 129/228) mortality. Cutaneous lesions were usually asymptomatic (26.3%, n = 81/308) and localized to the trunk (57.7%, n = 206/357) and extremities (56.8%, n = 203/357). Systemic involvement developed within 2 years on average, ranging from 0 to 28 years. Anti-platelet monotherapy had a complete resolution rate of 42.3% (n = 11/26) in BAP and 20.0% (n = 7/35) in MAP. Based on the findings of the study, most cases of Degos disease are malignant with high mortality, and even benign cutaneous cases may develop systemic disease in as late as 28 years. Anti-platelet monotherapies may prove effective against both variants. Further studies are needed to confirm these findings.
Flat scalp melanoma dermoscopic and reflectance confocal microscopy features correspond to histopathologic type and lesion location
F. Garbarino,R. Pampena,M. Lai,A.R. Pereira,S. Piana,A.M. Cesinaro,E. Cinotti,D. Fiorani,S. Ciardo,F. Farnetani,J. Chester,G. Pellacani,P. Guitera,C. Longo
doi : 10.1111/jdv.17313
Volume 35, Issue 8 p. 1670-1677
Dermoscopy and Reflectance Confocal Microscopy (RCM) features of scalp melanoma according to lesion location and histopathology have not been fully investigated.
Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany – The non-interventional study NIELS
R. Gutzmer,H.-J. Schulze,A. Hauschild,U. Leiter,F. Meier,S. Haferkamp,C. Ulrich,R.U. Wahl,C. Berking,R. Herbst,M. H?ckl,D. Schadendorf
doi : 10.1111/jdv.17332
Volume 35, Issue 8 p. 1678-1685
Basal cell carcinoma (BCC) can arise by the uncontrolled proliferation of cells from multiple epidermal compartments due to aberrant activation of the Hedgehog (Hh) signalling pathway. Vismodegib, a small-molecule inhibitor of this pathway, is approved for treatment of patients with locally advanced (la) BCC inappropriate for surgery or radiotherapy or patients with symptomatic metastatic (m) BCC.
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial
D. Thaçi,A.M. Soliman,K. Eyerich,A. Pinter,M. Sebastian,K. Unnebrink,S. Rubant,D.A. Williams,P. Weisenseel
doi : 10.1111/jdv.17109
Volume 35, Issue 8 p. 1686-1691
In a phase 3 clinical study, patients from Germany with moderate to severe psoriasis who were naïve to systemic treatment and received risankizumab had greater and more rapid disease improvements compared with those who received fumaric acid esters (FAEs).
Validation of questionnaire algorithm based on repeated open application testing with the constituents of fragrance mix II: the EDEN Fragrance Study
M. Bruze,M. Engfeldt,P. Elsner,M. Gonçalo,L. Naldi,M.L.A. Schuttelaar,C. Svedman,?. Svensson,R. Ofenloch
doi : 10.1111/jdv.17315
Volume 35, Issue 8 p. 1692-1701
In a European study on contact allergy in the general population, it has been hypothesized that the combination of contact allergy to a fragrance together with a history indicating dermatitis at exposure and thereafter subsequent avoidance of scented products implied a diagnosis of allergic contact dermatitis.
The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid
S. St?nder,C.M. Hammers,A. Vorobyev,E. Schmidt,D. Zillikens,S. Ghorbanalipoor,K. Bieber,R.J. Ludwig,K. Kridin
doi : 10.1111/jdv.17303
Volume 35, Issue 8 p. 1702-1711
The influence of cutaneous cellular infiltration on the phenotype of bullous pemphigoid (BP) remains to be established.
Lymphogranuloma venereum: a retrospective analysis of an emerging sexually transmitted disease in a Lisbon Tertiary Center
J.M. Neves,R. Ramos Pinheiro,R. Côrte-Real,M.J. Borrego,A. Rodrigues,C. Fernandes
doi : 10.1111/jdv.17302
Volume 35, Issue 8 p. 1712-1716
Lymphogranuloma venereum (LGV) is a sexual transmitted infection (STI), currently endemic within the population of men who have sex with men (MSM) of Western Countries. L2B variant has been reported as the predominant strain in the current LGV epidemics, although a shift towards L2-434 has been observed in some European countries.
Aquagenic wrinkling of the palms after brief immersion to water test as a screening tool for cystic fibrosis diagnosis
A. Alexopoulos,G. Chouliaras,T. Kakourou,M. Dakoutrou,L. Nasi,A. Petrocheilou,S. Siahanidou,C. Kanaka-Gantenbein,G. Chrousos,I. Loukou,A. Michos
doi : 10.1111/jdv.17312
Volume 35, Issue 8 p. 1717-1724
Aquagenic wrinkling of the palms (AWP) is an excessive and early palmar wrinkling occurring after Brief Immersion to Water (BIW), and has been reported as a frequent finding among cystic fibrosis (CF) patients.
Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: A 24-week prospective randomized placebo-controlled study
E. Fontas,H. Montaudié,T. Passeron
doi : 10.1111/jdv.17331
Volume 35, Issue 8 p. 1725-1729
Despite a solid rationale, the usefulness of antioxidants in treating vitiligo has not been clearly demonstrated. Combining superoxide dismutase (SOD) with a wheat gliadin biopolymer protects it during the passage through the gastrointestinal tract.
Nail changes as manifestation of systemic disease in COVID-19 infection
S.S. Ocampo-Garza,J. Ocampo-Candiani,E. Camela,M. Vastarella,G. Fabbrocini,M. Scalvenzi,A. Villani
doi : 10.1111/jdv.17273
Volume 35, Issue 8 p. e474-e475
Recurrence of previous chilblain lesions during the second wave of COVID-19: can we still doubt the correlation with SARS-CoV-2?
S. Signa,A.R. Sementa,M.C. Coccia,C. Pastorino,G. Viglizzo,S. Viola,S. Volpi,C. Occella,D. Bleidl,M. Acquila,E. Castagnola,A. Ravelli,F. Manunza
doi : 10.1111/jdv.17283
Volume 35, Issue 8 p. e475-e477
COVID-19-triggered sarcoidal granulomas mimicking scar sarcoidosis
A. Polat Ekinci,N. Büyükbabani,S. Me?e,G. Pehlivan,N.G. Okumu?,A. A?açfidan,E. ?zkaya
doi : 10.1111/jdv.17286
Volume 35, Issue 8 p. e477-e480
Under-representation of people of African ancestry in publications on the cutaneous manifestations of COVID-19: coincidence or physiology?
C Cassius,L Frumholtz,A de Masson,O Dadzie,A Petit, on behalf of Saint-Louis CORE (COvid Research) group
doi : 10.1111/jdv.17289
Volume 35, Issue 8 p. e480-e481
Adverse skin reactions related to PPE among healthcare workers managing COVID-19
P. Sharma,N. Goel,K. Dogar,M. Bhalla,G.P. Thami,K. Punia
doi : 10.1111/jdv.17290
Volume 35, Issue 8 p. e481-e483
Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series
M. Corbeddu,A. Diociaiuti,M.R. Vinci,A. Santoro,V. Camisa,S. Zaffina,M. El Hachem
doi : 10.1111/jdv.17268
Volume 35, Issue 8 p. e483-e485
Incidence and prognosis of COVID-19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study
J.R. Georgakopoulos,A. Mufti,R. Vender,V.H. Prajapati,J. Yeung
doi : 10.1111/jdv.17279
Volume 35, Issue 8 p. e485-e487
Penile ischaemia secondary to COVID-19: why should the dermatologist be concerned?
P. Sarkis,J. Sarkis,M. Alkassis,J. Assaf,K. El Gharib
doi : 10.1111/jdv.17287
Volume 35, Issue 8 p. e487-e489
Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance
J.M. Busto-Leis,G. Servera-Negre,A. Mayor-Ibarguren,E. Sendagorta-Cud?s,M. Feito-Rodr?guez,A. Nu?o-Gonz?lez,M.D. Montero-Vega,P. Herranz-Pinto
doi : 10.1111/jdv.17301
Volume 35, Issue 8 p. e489-e491
Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report
E. Akda?,N. ?lter,B. ??üt,?. Erdem
doi : 10.1111/jdv.17316
Volume 35, Issue 8 p. e491-e493
BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2
V. Piccolo,A. Bassi,G. Argenziano,C. Mazzatenta,M. Cutrone,I. Neri,R. Grimalt,T. Russo
doi : 10.1111/jdv.17320
Volume 35, Issue 8 p. e493-e494
Extraordinary claims without extraordinary evidence: controversy on anti-androgen therapy for COVID-19
R.M. Trüeb,A. Régnier,N. Caballero-Uribe,M.F. Reis Gavazzoni Dias,H. Dutra Rezende
doi : 10.1111/jdv.17249
Volume 35, Issue 8 p. e494-e495
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies
K.J. Mason,A.D. Burden,J.N.W.N. Barker,M. Lunt,H. Ali,C.E. Kleyn,K. McElhone,M.M. Soliman,A.C. Green,C.E.M. Griffiths,N.J. Reynolds,A.D. Ormerod, on behalf of the BADBIR Study Group
doi : 10.1111/jdv.17282
Volume 35, Issue 8 p. e496-e498
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR
K.J. Mason,A.D. Burden,J.N.W.N. Barker,M. Lunt,H. Ali,C.E. Kleyn,K. McElhone,M.M. Soliman,A.C. Green,C.E.M. Griffiths,N.J. Reynolds,A.D. Ormerod,the BADBIR Study Group
doi : 10.1111/jdv.17230
Volume 35, Issue 8 p. e498-e501
Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy
R. Maglie,F. Ugolini,F. De Logu,S. Simi,S. Senatore,F. Montefusco,R. Nassini,D. Massi,E. Antiga
doi : 10.1111/jdv.17232
Volume 35, Issue 8 p. e501-e503
Pre-ulcerative leishmaniasis mimicking chilblains in a returning traveller from Southern Europe
J. Nasri,L. Cajacob,E. Wirz,M.-T. Ruf,J. Blum,B. Mühleisen,A. A. Navarini,L. V. Maul
doi : 10.1111/jdv.17233
Volume 35, Issue 8 p. e503-e505
Chondrodermatitis nodularis helicis in the 21st century: demographic trends from a gender and age perspective. A single University hospital retrospective histopathological register study of 215 patients in Asturias, North Spain (2000–2017)
F. V?zquez-L?pez,B. G?mez-Vila,B. V?zquez-Losada,L. Palacios Garc?a,B. Vivanco-Allende,C. G?mez de Castro
doi : 10.1111/jdv.17234
Volume 35, Issue 8 p. e506-e507
Teledermoscopy of common pink, flat and scaly lesions as an adjuvant diagnostic method in everyday clinical practice: so far, so close
I. Papadimitriou,K. Bakirtzi,E. Sotiriou,A. Lallas,E. Vakirlis,E. Lazaridou,D. Ioannides
doi : 10.1111/jdv.17235
Volume 35, Issue 8 p. e507-e509
Line-field confocal optical coherence tomography of sebaceous hyperplasia: a case series
C. Lenoir,G. Diet,E. Cinotti,L. Tognetti,C. Orte Cano,L. Rocq,A.-L. Trépant,J. Monnier,J. Perez-Anker,P. Rubegni,S. Puig,J. Malvehy,J.-L. Perrot,V. del Marmol,M. Suppa
doi : 10.1111/jdv.17251
Volume 35, Issue 8 p. e509-e511
Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study
C. Juzot,V. Sibaud,F. Amatore,S. Mansard,V. Seta,G. Jeudy,A. Pham-Ledard,M. Benzaquen,L. Peuvrel,Y. Le Corre,C. Lesage,M. Viguier,B. Baroudjian,B. Dréno,G. Quéreux
doi : 10.1111/jdv.17253
Volume 35, Issue 8 p. e511-e514
Myriad of pigmented lesions in a patient with Costello syndrome
V. Schremser,C. Sinz,A. Tanew,S. Radakovic
doi : 10.1111/jdv.17254
Volume 35, Issue 8 p. e514-e516
Combined Methotrexate and Alitretinoin for the treatment of difficult-to-treat generalized prurigo nodularis: a case series
C. Bergqvist,C. Fiani,A. Simantov,C. Lebre,C. Hua,N. Ortonne,P. Wolkenstein,O. Chosidow
doi : 10.1111/jdv.17262
Volume 35, Issue 8 p. e516-e519
A case of anaphylactic shock induced by mealworm antigen in the bite of a Japanese flying squirrel
H. Seshimo,T. Ito,C. Egusa,T. Numata,T. Kobayashi,N. Abe,T. Niitsuma,Y. Okubo,K. Harada
doi : 10.1111/jdv.17265
Volume 35, Issue 8 p. e519-e520
Hidradenitis suppurativa and sleep disorders: a population-based study
J.M. Cohen,K. Kridin,L.M. Perez-Chada,J.F. Merola,A.D. Cohen
doi : 10.1111/jdv.17293
Volume 35, Issue 8 p. e520-e522
DNA-chip-based molecular testing as a clue for the diagnosis of tinea: a case series
S. St?nder,L. Ha,K. Kridin,K. Bieber,D. Zillikens,R.J. Ludwig,W. Anemüller,K. Boch
doi : 10.1111/jdv.17296
Volume 35, Issue 8 p. e522-e524
Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin chloride 10%
G. Kontochristopoulos,V. Markantoni,E. Agiasofitou,E. Platsidaki,A. Kouris,A. Campanati,A.M. Offidani,D. Rigopoulos,S. Gregoriou
doi : 10.1111/jdv.17297
Volume 35, Issue 8 p. e524-e526
Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1
W. Cantrell,P. Lee,A.M. Mendelsohn,S.J. Rozzo,W. Liao
doi : 10.1111/jdv.17124
Volume 35, Issue 8 p. e526-e528
Intravenous allogeneic multilineage-differentiating stress-enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open-label study
Y. Fujita,T. Nohara,S. Takashima,K. Natsuga,M. Adachi,K. Yoshida,S. Shinkuma,T. Takeichi,H. Nakamura,O. Wada,M. Akiyama,A. Ishiko,H. Shimizu
doi : 10.1111/jdv.17201
Volume 35, Issue 8 p. e528-e531
Characterization of non-responders to interleukin-17 inhibitors in moderate to severe psoriasis patients enrolled in the Corrona® Psoriasis Registry
J.J. Wu,D.G. Kearns,T.-c. Lin,V.S. Chat,H.J. Litman,B. Dube,R.R. McLean
doi : 10.1111/jdv.17270
Volume 35, Issue 8 p. e531-e533
A single-centre real-life experience on effectiveness and safety of dupilumab in adolescents with severe atopic dermatitis in treatment with cyclosporine A
C. Colonna,M. Zussino,A. Ponziani,C. Gelmetti,N.A. Monzani
doi : 10.1111/jdv.17280
Volume 35, Issue 8 p. e533-e535
COL17A1 gene polymorphisms are frequent in bullous pemphigoid
P.-S. Tabatabaei-Panah,H. Moravvej,M. Alirajab,F. Arghand,H. Babaei,E. Didehvar,S. Hajmanouchehri,F. Hosseine,A. Karimi,M. Mahdian,S. Parvizi Moridani,F. Sakhaie,R.J. Ludwig,R. Akbarzadeh
doi : 10.1111/jdv.17285
Volume 35, Issue 8 p. e535-e538
